Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly

Table 1

Baseline characteristics and statistical comparisons within the entire intervention group, and stratified by sparse or dense tumor granulation. p ≤ 0.05.

Variable	Whole group	Densely granulated	Sparsely granulated	p-value
Group size	36	18	18	N/A
Age	48.1 (11.7)	50.6 (11.0)	45.6 (12.2)	0.20
Female sex	17 (47%)	7 (39%)	10 (56%)	0.32
Radiotherapy	6 (17%)	1 (6%)	5 (28%)	0.074
Macroadenoma	30 (83%)	15 (83%)	15 (83%)	0.99
Suprasellar extension abutting the optic chiasm	14 (39%)	8 (44%)	6 (33%)	0.49
Cavernous sinus invasion	18 (51%)	9 (53%)	9 (50%)	0.86
Sphenoid sinus invasion	6 (17%)	3 (17%)	3 (17%)	0.99
High MR T2-Signal	7 (19%)	1 (6%)	6 (33%)	0.035
Maximal initial diameter (mm)	16 (12.0, 21.0)	15.0 (11.0, 20.0)	16.0 (12.0, 24.0)	0.65
GH before treatment (μg/mL)	7.85 (5.25, 25.4)	13.3 (5.8, 26.8)	7.3 (4.8, 24.0)	0.41
IGF-1 before treatment (ng/mL)	856.5 (606.5, 1336.5)	961.0 (705.0, 1500.0)	851.5 (583.0, 955.0)	0.22
Ki-67	1.0 (0.5, 2.0)	1.0 (0.5, 1.0)	2.0 (1.0, 3.5)	0.013
SSTR-2	3.0 (1.0, 3.0)	3.0 (1.0, 3.0)	2.5 (1.0, 3.0)	0.29
SSTR-5	1.0 (0.0, 3.0)	1.0 (0.0, 3.0)	1.0 (1.0, 3.0)	0.80
ZAC-1	0.5 (0.0, 2.0)	1.0 (0.0, 2.0)	0.0 (0.0, 1.0)	0.061
E-cadherin	1.0 (0.0, 2.0)	2.0 (1.0, 3.0)	0.0 (0.0, 2.0)	0.067
AIP	3.0 (3.0, 3.0)	3.0 (3.0, 3.0)	3.0 (2.0, 3.0)	0.25